Antisense modulation of serum amyloid A4 expression
First Claim
Patent Images
1. A compound 18 to 50 nucleobases in length targeted to nucleobases 114 through 137, nucleobases 158 through 223, nucleobases 230 through 249, nucleobases 282 through 357, or nucleobases 385 through 406 of a coding region of a nucleic acid molecule encoding human serum amyloid A4 of SEQ ID NO:
- 3, wherein said compound specifically hybridizes with one of said regions and inhibits the expression of human serum amyloid A4.
1 Assignment
0 Petitions
Accused Products
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of serum amyloid A4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding serum amyloid A4. Methods of using these compounds for modulation of serum amyloid A4 expression and for treatment of diseases associated with expression of serum amyloid A4 are provided.
-
Citations
26 Claims
-
1. A compound 18 to 50 nucleobases in length targeted to nucleobases 114 through 137, nucleobases 158 through 223, nucleobases 230 through 249, nucleobases 282 through 357, or nucleobases 385 through 406 of a coding region of a nucleic acid molecule encoding human serum amyloid A4 of SEQ ID NO:
- 3, wherein said compound specifically hybridizes with one of said regions and inhibits the expression of human serum amyloid A4.
- View Dependent Claims (2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
3. A compound up to 50 nucleobases in length comprising at least an 18 nucleobase portion of SEQ ID NO:
- 14, 16, 17, 19, 20, 21, 24, 26, 28, 29, 36, 38, 41, 49, 53, 58, 59, 60, 61, 65 or 69 which inhibits the expression of human serum amyloid A4.
- View Dependent Claims (15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)
Specification